Novo Says More Patients Helped by Victoza When Treated Early
This article is for subscribers only.
Novo Nordisk A/S said a study shows more patients benefit from its diabetes drug Victoza when the medicine is prescribed early in the disease.
Scientists delving into data from an existing study found that 72 percent of those treated early with Victoza met a target of lower blood-sugar levels, compared with 49 percent of those treated late, the Bagsvaerd, Denmark-based drugmaker said in a statement today.